A year of building, encounters, and new connections. Thank you for being here. Here is our annual report for 2025.
2025 was a year of building for Psychedelia Foundation, shaped by exchange, encounters, and new connections. We listened, joined conversations, supported initiatives, and strengthened relationships. Thank you for your attention, your questions, and your trust.
Precisely because the field around psychedelic research and therapy is developing quickly, we want to offer orientation and emphasize responsibility. With clear language, respect for sensitive contexts, and focus on what genuinely helps in practice, research, and public discourse.
Below, we share insights into the topics, structures, and encounters that shaped our year.
2025 at a glance
- Growth of the Scientific Advisory Board, currently nine members
- Contributions and presence in professional contexts, from summits to conferences
- Co-organisation and workshop work in the area of ketamine therapy
- Cultural and public dialogue formats in Berlin
- Collaboration in a sensitive BIPOC context with a research component
Scientific Advisory Board
Building our Scientific Advisory Board was one of the most important steps this year. We are now supported by nine advisors from different disciplines as an independent, consultative voice. They provide Psychedelia-Foundation with strategic, scientific, professional, and ethical guidance, so our work remains well grounded in research, public health, and education. Decisions and responsibility continue to rest with the Board of Directors.
In practical terms, this means one thing above all: we can discuss important questions with greater depth before decisions are made or new priorities are set.
The Board brings together diverse perspectives and provides guidance on strategic, scientific, professional, and ethical questions. Its role is consultative. Operational work and all decisions remain with the Board of Directors.
You can find the current overview on our About Us page.
Conferences and professional events 2025
In 2025, we participated in a range of conferences and professional events to contribute, listen, and engage in meaningful exchange:
- Psychedelika Summit, Hildesheim:
A one-day conference with talks, workshops, and networking in Hildesheim. Sergio Pérez Rosal and Markus Berger gave talks. - Psychedelic Science 2025, Denver (June 16 to 20, 2025): An international MAPS conference at the Colorado Convention Center in Denver. Sergio Pérez Rosal presented a poster.
- Holistic Health Festival, Berlin (September 2025): A health festival at the Museum für Naturkunde Berlin with a program focused on holistic perspectives on health. Sergio Pérez Rosal contributed through a program session.
- International Ketamine Conference, Frankfurt (October 18 to 25, 2025): An international continuing-education conference for physicians and psychotherapists at the Marriott Hotel Frankfurt Messe. Organized by Dr. Scheib, with Psychedelia-Stiftung as co-organiser. Sergio Pérez Rosal gave a talk, and Sergio Pérez Rosal and Francieli Favarim facilitated a workshop.
What connects these events is that the questions are becoming more concrete. Less buzzwords, more practice, competencies, and responsibility.
Culture and public dialogue in Berlin
Cultural evening at Soho House (November 13, 2025)
An evening with Murari and Alessandra Afausto of the Shanenawa community. It was important to us to create a respectful setting that enables encounter, without projection, romanticization, or simplification.
Healthy Drugs Live-Podcast, The New Health Club bei Acht Berlin (19. November 2025)
Ein Live-Podcast-Format, veranstaltet von Anne Philippi und The New Health Club, bei Acht Berlin, mit Lars Wilde, Julia Bamberg und Sergio Pérez Rosal. Öffentliche Gespräche dieser Art sind wichtig, weil sie Nuancen zulassen und Polarisierung entgegenwirken können. Weniger Meinung, mehr Kontext.
Focus 2025: Collaboration with a research component
Racial Trauma Retreat in Jamaica (July 2025)
In collaboration with the University of Ottawa, a retreat format with a research component was implemented. The target group was BIPOC, meaning Black, Indigenous, and People of Color, in the context of racialized trauma. Eleven people participated. The format was successful, and the next iteration is planned for March 2026.
Framework and context
In formats like this, context is essential. Our priority was that facilitation, safety, and integration were implemented professionally, and that the language around the topic remained responsible.
Concretely, this meant:
- A clearly defined professional framework that makes roles, responsibilities, and processes transparent
- Trauma-informed practice and integration as a core component, not an add-on
- Respect for cultural contexts and representation without romanticizing or simplifying imagery
- Clear boundaries around what is communicated and what is not, to avoid false expectations
Developments in Europe: from debate to frameworks
Europe remains diverse, with different legal systems, care pathways, and assessment logics. At the same time, 2025 showed in several places that the discussion is becoming more concrete. Less slogans, more questions about frameworks, quality, and patient protection.
Germany: access, regulation, training
In Germany, it is becoming increasingly clear that implementing psychedelic-assisted therapy is not only a question of studies. Three elements must work together in the health system: access pathways for patients, rules for assessment and reimbursement, and training and competencies of the professionals involved.
In this context, the existing legal framework for hardship programs, meaning compassionate use, becomes more relevant. It shows how theory can translate into practice when new treatments are to be implemented responsibly in clearly defined settings.
A more detailed perspective can be found in our article „What Does Germany Need for Psychedelic-Assisted Therapy?“
Switzerland: limited medical access as a reference point
Switzerland has long worked with exceptional authorizations for limited medical applications. For Europe, this is relevant because it creates practical experience, for example regarding indications, qualifications, risk management, and documentation. Further information on the Swiss model of exceptional authorizations can be found here.
EU: Health Technology Assessment becomes more important
Since January 12, 2025, EU-wide joint clinical assessments for certain new medicines have been phased in. For innovative therapies, this means that assessment and classification increasingly influence how evidence is later translated into care and reimbursement. Further information on the EU HTA regulation and joint clinical assessments can be found here.
Looking ahead to 2026 and invitation
A closing thought from the past year: in a field that generates so much hope but also so many misunderstandings, precise language, competent practice, and strong relationships are not secondary. They are the prerequisite.
With the Scientific Advisory Board and all the conversations that were possible in 2025, we laid an important foundation. In 2026, we want to build on that by making orientation more accessible, keeping exchange reliable, and staying precise where topics are sensitive.
Thank you for accompanying us. If you would like to stay connected:
- Follow us on LinkedIn and Instagram for occasional updates.
- For collaborations and professional exchange, reach us via the contact page.
- If you would like to support our charitable work, we are grateful for donations or partnerships.
Warm regards,
Your Psychedelia Foundation team
